Schear Investment Advisers LLC Acquires Shares of 3,102 Medpace Holdings, Inc. $MEDP

Schear Investment Advisers LLC bought a new stake in Medpace Holdings, Inc. (NASDAQ:MEDP) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 3,102 shares of the company’s stock, valued at approximately $1,490,000.

A number of other institutional investors have also modified their holdings of the stock. Geneos Wealth Management Inc. raised its position in Medpace by 64.9% during the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after buying an additional 37 shares during the last quarter. Steigerwald Gordon & Koch Inc. purchased a new stake in shares of Medpace in the fourth quarter valued at about $30,000. Elyxium Wealth LLC purchased a new stake in shares of Medpace in the fourth quarter valued at about $30,000. Quarry LP acquired a new position in shares of Medpace during the third quarter worth about $35,000. Finally, Bayban acquired a new position in shares of Medpace during the fourth quarter worth about $44,000. Institutional investors and hedge funds own 77.98% of the company’s stock.

Medpace Stock Down 1.8%

NASDAQ MEDP traded down $10.36 during mid-day trading on Tuesday, hitting $554.73. The stock had a trading volume of 80,232 shares, compared to its average volume of 354,389. The company has a 50 day simple moving average of $457.31 and a 200 day simple moving average of $496.24. The company has a market cap of $15.84 billion, a price-to-earnings ratio of 34.76, a P/E/G ratio of 2.83 and a beta of 1.15. Medpace Holdings, Inc. has a 52-week low of $306.70 and a 52-week high of $628.92.

Medpace (NASDAQ:MEDP) last posted its earnings results on Wednesday, April 22nd. The company reported $4.28 EPS for the quarter, topping analysts’ consensus estimates of $3.74 by $0.54. Medpace had a return on equity of 120.89% and a net margin of 17.19%.The company had revenue of $706.60 million for the quarter, compared to the consensus estimate of $697.82 million. During the same period in the previous year, the business earned $3.67 earnings per share. Medpace’s quarterly revenue was up 26.5% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. As a group, equities analysts anticipate that Medpace Holdings, Inc. will post 17.04 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, General Counsel Stephen P. Ewald sold 16,349 shares of the stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $450.00, for a total value of $7,357,050.00. Following the sale, the general counsel directly owned 20,343 shares of the company’s stock, valued at approximately $9,154,350. This represents a 44.56% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 20.50% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on MEDP shares. Robert W. Baird cut their price target on shares of Medpace from $565.00 to $477.00 and set an “outperform” rating for the company in a report on Friday, April 24th. Wall Street Zen cut Medpace from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. BMO Capital Markets cut their target price on Medpace from $460.00 to $400.00 and set a “market perform” rating for the company in a research note on Friday, April 24th. Barclays reduced their price target on Medpace from $500.00 to $450.00 and set an “equal weight” rating for the company in a report on Friday, April 24th. Finally, Weiss Ratings restated a “hold (c+)” rating on shares of Medpace in a research note on Thursday. Three investment analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $463.33.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.